Albany Molecular Research Reaches New 12-Month High at $21.14 (AMRI)
Albany Molecular Research (NASDAQ:AMRI) hit a new 52-week high on Tuesday , American Banking News.com reports. The stock traded as high as $21.14 and last traded at $20.99, with a volume of 928,276 shares traded. The stock had previously closed at $20.12.
AMRI has been the subject of a number of recent research reports. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Albany Molecular Research in a research note on Wednesday, June 11th. They now have a $21.00 price target on the stock, up previously from $19.00. Separately, analysts at TheStreet upgraded shares of Albany Molecular Research from a “hold” rating to a “buy” rating in a research note on Wednesday, June 4th. Finally, analysts at TheStreet downgraded shares of Albany Molecular Research from a “buy” rating to a “hold” rating in a research note on Thursday, May 15th.
The stock has a 50-day moving average of $17.51 and a 200-day moving average of $14.91. The company has a market cap of $669.4 million and a P/E ratio of 66.40.
Albany Molecular Research (NASDAQ:AMRI) last issued its quarterly earnings results on Tuesday, May 6th. The company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by $0.07. The company had revenue of $51.00 million for the quarter, compared to the consensus estimate of $62.19 million. On average, analysts predict that Albany Molecular Research will post $0.88 earnings per share for the current fiscal year.
Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.